



CYFARFOD BWRDD PRIFYSGOL IECHYD UNIVERSITY HEALTH BOARD MEETING

DYDDIAD Y CYFARFOD: DATE OF MEETING:	25 March 2021
TEITL YR ADRODDIAD: TITLE OF REPORT:	Hywel Dda University Health Board Pharmaceutical Needs Assessment
CYFARWYDDWR ARWEINIOL: LEAD DIRECTOR:	Jill Paterson, Director of Primary Care, Community and Long Term Care
SWYDDOG ADRODD: REPORTING OFFICER:	Jenny Pugh-Jones, Clinical Director of Pharmacy and Medicines Management

Pwrpas yr Adroddiad (dewiswch fel yn addas)

Purpose of the Report (select as appropriate)

Ar Gyfer Penderfyniad/For Decision

ADRODDIAD SCAA SBAR REPORT

Sefyllfa / Situation

Health Boards in Wales are required by section 82A of the Public Health (Wales) Act and enacted by The National Health Service (Pharmaceutical Services) (Wales) Regulations 2020, to publish a pharmaceutical needs assessment by 1st October 2021.

In response to this statutory duty, the Health Board has gathered intelligence from a range of sources to prepare the Hywel Dda University Health Board's preliminary Pharmaceutical Needs Assessment 2021-2026. This technical document includes data and feedback from patient and contractor surveys, Public Health Wales and information on existing commissioned services from community pharmacy. A Welsh version will be available.

The Board is asked to approve the full document (available [here](#)), along with the summary document (Appendix 1) and questionnaire (Appendix 2), which have been prepared for the next stage of public consultation.

Cefndir / Background

Since the 1980s, applications to provide community pharmacy services have been assessed by Health Boards, and their predecessors, by means of the "control of entry" test. An application to provide pharmacy services is likely to succeed only where a Health Board considers it necessary and expedient to grant it in order to secure adequate pharmacy services within the defined neighbourhood.

This process focussed largely upon the dispensing of prescriptions by applicants and does not address the increasing number of additional pharmacy services, including emergency contraception, influenza vaccination, common ailments scheme and smoking cessation.

Through section 82A of the Public Health Act and enacted by The National Health Service (Pharmaceutical Services) (Wales) Regulations 2020, Health Board are required to publish a pharmaceutical needs assessment by 1st October 2021.

Asesiad / Assessment

Rationale

The under-pinning rationale for introducing a Pharmaceutical Needs Assessment (PNA) is to ensure the full range of community pharmacy services are taken into account and aligned with general primary care services and that decisions on the level and extent of community pharmacy services are grounded in addressing the identified health care needs of the local population. The most significant change introduced under the Act relates to the way in which Health Boards make decisions on applications to the Health Board Pharmaceutical List (currently known as Control of Entry). Under the existing 2013 regulations, the location of a pharmacy is dependent upon the contractor deciding to make an application. When Health Boards determine these applications they are limited to considering need in terms of dispensing services only. No account may be taken of the wider health care needs such as extended opening hours, influenza vaccinations or common ailment services, to reduce pressure on GP services and improve patient access to care.

Effect/Impact

The new PNA regulations will change fundamentally how Control of Entry decisions are made, by shifting from a system that is driven by the contractors and focused heavily on dispensing, to a system led by the NHS that responds to the wider pharmaceutical needs of local communities. The requirements for a PNA will be aligned with other health needs assessment requirements, to support a holistic and comprehensive approach to needs assessment. This approach will allow the Health Board to align Community Pharmacy services with its strategic intent of moving services closer to home and supporting our population in their local communities.

A PNA will cover the full range of essential, advanced and enhanced services under the Community Pharmacy Contract Framework. This will enable Health Boards to consider the level and extent of pharmaceutical services required to meet the needs of their population and to do that in the context of their plans and priorities for primary care services and the wider strategic direction of the Health Board.

Dispensing Doctors

The 2013 regulations governing Control of Entry to the pharmaceutical list will be abolished. However, the current arrangements for dispensing doctors as reflected in those regulations will remain the same and will be included in the new PNA regulations.

Timeframe

The new regulations came into force in April 2020. There is a statutory requirement upon Health Boards to have published a first PNA by 1st October 2021.

Each PNA must be subject to a minimum of 60 days consultation prior to publication. Hywel Dda University Health Board's **draft** PNA is now complete and should be available for consultation in **April 2021** in order to allow sufficient opportunity to reflect upon consultation responses prior to publication of the final PNA by **October 1st 2021**.

From October 2021, all applications to the Pharmaceutical List must demonstrate how they will meet any identified need set out in the PNA. Consideration of applications will be in the context of the published PNA.

The Pharmaceutical Needs Assessment will be in effect for a period of 5 years from 1st October 2021, at which time it will be republished, following a period of review, unless there are sufficient changes to local need in the interim.

Next Steps

- On approval of the PNA, the summary document and questionnaire, the Health Board will progress to the formal Public Consultation stage.
- An easy read document will be developed to increase public engagement.
- The Public Consultation will begin on Monday 19th April 2021, unless otherwise advised.
- The Public Consultation stage will run for 6 weeks, in line with national standards
- The responses will be collated and reviewed with a final document submitted to the Board in either July or September 2021.

Argymhelliad / Recommendation

The Board is asked to:

- **NOTE** the change in legislation and future implications for pharmaceutical services;
- **APPROVE** the draft Pharmaceutical Needs Assessment and associated documents to allow public consultation.

Amcanion: (rhaid cwblhau)

Objectives: (must be completed)

Cyfeirnod Cofrestr Risg Datix a Sgôr Cyfredol: Datix Risk Register Reference and Score:	1047 (After mitigation score 4)
Safon(au) Gofal ac Iechyd: Health and Care Standard(s): Hyperlink to NHS Wales Health & Care Standards	1. Staying Healthy 1.1 Health Promotion, Protection and Improvement
Amcanion Strategol y BIP: UHB Strategic Objectives: Hyperlink to HDdUHB Strategic Objectives	2. Living and working well
Amcanion Llesiant BIP: UHB Well-being Objectives: Hyperlink to HDdUHB Well-being Objectives Annual Report 2018-2019	4. Improve Population Health through prevention and early intervention, supporting people to live happy and healthy lives

Gwybodaeth Ychwanegol:

Further Information:

Ar sail tystiolaeth: Evidence Base:	82A of the Public Health (Wales) Act and enacted by The National Health Service (Pharmaceutical Services)(Wales) Regulations 2020 Letter from Director General Health and Social Services WG (30 th April 2018, 23 rd May 2019)
--	--

Rhestr Termâu: Glossary of Terms:	Contained within the body of the report
Partïon / Pwyllgorau â ymgynhorwyd ymlaen llaw y Cyfarfod Bwrdd Iechyd Prifysgol: Parties / Committees consulted prior to University Health Board:	Primary Care Contracts and Senior Pharmacist Leadership Team. PNA Steering Group.

Effaith: (rhaid cwblhau) Impact: (must be completed)	
Ariannol / Gwerth am Arian: Financial / Service:	There are potential financial risks of funding additional pharmaceutical contracts if gaps in pharmaceutical need are identified.
Ansawdd / Gofal Claf: Quality / Patient Care:	The new PNA regulations will change fundamentally how the Community Pharmacy Control of Entry decisions are made, by shifting from a system that is driven by the contractors and focused heavily on dispensing, to a system led by the NHS that responds to the wider pharmaceutical needs of local communities. This approach should improve access to care, widen the enhanced services provided by community pharmacies and support the inverse care principles of targeting health care provision where there is the greatest need.
Gweithlu: Workforce:	N/A
Risg: Risk:	There is a risk of non-compliance to the legal requirement set out in section 82A of the Public Health (Wales) Act and enacted by The National Health Service (Pharmaceutical Services) (Wales) Regulations 2020, to publish a Pharmaceutical Needs Assessment (PNA) by 1 st October 2021.
Cyfreithiol: Legal:	82A of the Public Health (Wales) Act and enacted by The National Health Service (Pharmaceutical Services) (Wales) Regulations 2020.
Enw Da: Reputational:	Legal requirement to complete and publish by October 2021.
Gyfrinachedd: Privacy:	N/A
Cydraddoldeb: Equality:	The PNA will need to incorporate the provision of the Equality Act 2010 to ensure that the assessment of pharmaceutical need considers the protected characteristics under the Act.